Seeking Alpha

Geron presents imetelstat data at ASH, shares rise

  • Shares of Geron (GERN) rose 9% in AH trading.
  • In a closely watched presentation at ASH, the company reviewed results from a study of imetelstat in myelofibrosis. For reference, see previous coverage of the study here and here.
  • Results of GERN independent review of the Mayo study: Remissions (CR+PR) in 5/22 patients; CI in another 4 patients; OR rate of 40.9%.
  • Notable: GERN says "no patients with CR, PR, or CI have lost their response to date."
  • This is an important study. For more, see the full presentation.
Comments (6)
  • This should be solidly up tomorrow. I was convinced by the data already before today and used the drop today to double my long position. $GERN on the way to success finally.
    9 Dec 2013, 10:03 PM Reply Like
  • Most impressive!
    9 Dec 2013, 10:04 PM Reply Like
  • This is a winner tomorrow. Get ready to buy.
    10 Dec 2013, 04:26 AM Reply Like
  • The short gang will be active.use this opportunity to buy.
    10 Dec 2013, 10:58 AM Reply Like
  • Short gang very active. Will be expensive for them because they will have to cover soon.
    10 Dec 2013, 12:31 PM Reply Like
  • I hung in there a LONG time waiting for this Company to prove it was on the right track..EVERYONE NOW KNOWS!!!!!
    10 Dec 2013, 02:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)